The DOI matches its Crossref record.
Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials
Open accessAbstract
Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on an analysis of 68 RCTs encompassing 60,720 participants, Shihab et al. [57] demonstrated that GLP-1 based agents were associated with a three-fold increased risk of pancreatic enzyme elevation relative to controls, yet did not indicate a significant rise in pancreatitis or pancreatic cancer.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [57]
In the citing paper
“Based on an analysis of 68 RCTs encompassing 60,720 participants, Shihab et al. [57] demonstrated that GLP-1 based agents were associated with a three-fold increased risk of pancreatic enzyme elevation relative to controls, yet did not indicate a significant rise in pancreatitis or pancreatic cancer.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [57]
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
“Based on an analysis of 68 RCTs encompassing 60,720 participants, Shihab et al. [57] demonstrated that GLP-1 based agents were associated with a three-fold increased risk of pancreatic enzyme elevation relative to controls, yet did not indicate a significant rise in pancreatitis or pancreatic…”
Chen, Y. H., Huang, C., Cho, Y. M., Li, P., Gu, L., Wang, F., Yang, J., & Wang, W. Q. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13340 · Cited by 43
Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis
Chen, S., Zhao, E., Li, W., & Wang, J. (2017) · Medicine · doi:10.1097/md.0000000000008952 · Cited by 11
Verhoogde kans op acute pancreatitis met GLP-1-analogen of DPP-4-inhibitoren?
Goderis, G. (2017) · Lirias
Metadata
- Authors
- Shihab, H. M.
- Corresponding author
- Shihab, Hasan M
- Venue
- World Journal of Meta-Analysis
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 3
- Issue
- 6
- Pages
- 254
- ISSN
- 2308-3840 (ISSN-L)
- OpenAlex
- W2759953463
- Cited by
- 5
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2018: 1 · 2017: 1 · 2016: 1
- FWCI
- 0.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- World Journal of Meta-Analysis (publishedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, DPP-4 inhibitors, drug safety, type 2 diabetes, drug-induced pancreatitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
